- recruitingPHASE2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
This study is testing a new oral medicine, APL-101, for people with advanced cancers. It focuses on lung cancer and other solid tumours where specific genetic changes linked to a protein called MET are found. Researchers want to see how well it works and if it's safe.
United States · Australia · Canada - recruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
United States · Argentina · Austria - active not recruitingPHASE1
Phase I Trial of Defactinib and VS-6766.
This study is testing two new drugs, Defactinib and VS-6766, for patients with advanced cancers like certain lung, ovarian, womb, and pancreatic cancers. It aims to find the safest dose and see how well the combination works.
United Kingdom - active not recruitingPHASE1
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
This study is testing a new medicine, IOA-244, for people with certain advanced cancers, including lymphoma and melanoma. It aims to see if the medicine is safe and if it can help the body's immune system fight cancer, both alone and with other treatments.
Italy · United Kingdom - active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
United States · Australia · Belgium - recruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - active not recruitingPHASE3
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
This study is testing a new combination of treatments for adults with advanced lung cancer (NSCLC) that hasn't spread to the brain or spine and doesn't have certain genetic changes. It compares this new treatment to a standard one, hoping it works better.
United States · Austria · Brazil - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients with Metastatic Non-squamous Non-small Cell Lung Cancer (LOTUS)
This study is comparing a new medication called FYB206 to a commonly used lung cancer drug, Keytruda. We want to see if FYB206 works just as well and is as safe for people with a certain type of advanced non-small cell lung cancer when given with chemotherapy.
Romania · Bulgaria · Poland - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Study of ZW171 in Participants with Advanced or Metastatic Mesothelin Expressing Cancers
This study is testing a new medicine, ZW171, for people with advanced or spreading cancers like ovarian, lung (NSCLC), and pancreatic cancer that have a specific protein called mesothelin. It's an early-stage study to see how safe the medicine is and if it works.
Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies
This study looks at a new combination of existing medicines for a type of lung cancer (NSCLC) that has worsened after previous treatments. It aims to see how many patients respond positively to this new treatment approach.
France - recruitingPHASE1, PHASE2
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
This study is testing a new medicine called EP0031 for advanced cancers caused by problems with a gene called RET. It aims to see if EP0031 is safe, what side effects it causes, and how well it works, especially for a type of lung cancer called NSCLC.
United States · France · Germany - recruitingPHASE1
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
This study is testing a new drug, OKN4395, alone and with an existing cancer treatment, pembrolizumab, for various solid tumours. The main goals are to check its safety, how well it's tolerated, and if it helps fight cancer.
United States · Australia · United Kingdom - recruitingPHASE1, PHASE2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This study is looking at a new drug called MCLA-158 for advanced cancers like bowel and head and neck cancer. It aims to find the safest dose and see how well it works alone or with other treatments. It's for patients whose cancer has spread or come back.
United States · Belgium · France - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A study to learn about the study medicine called PF-08046032 in people with advanced cancers.
This study is looking into a new medicine, PF-08046032, for people with advanced cancers like certain lymphomas and solid tumours. It's an early-stage study to understand how the medicine works and if it's safe for people aged 18 and over.
Spain